Release Summary

FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D), a Life-threatening and Ultra-rare Metabolic Disorder

Alexion Pharmaceuticals, Inc.